Skip to main content
. 2021 Mar 23;10(7):e018689. doi: 10.1161/JAHA.120.018689

Figure 4. NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) ≤1000 mg/dL and risk of adverse cardiovascular events.

Figure 4

A, The risk of adverse cardiovascular events stratified by achieved NT‐proBNP levels. B, The risk of adverse cardiovascular events stratified by obesity and having NT‐proBNP ≤1000 mg/dL. Adjusted for age, sex, race, blood urea nitrogen, left ventricular ejection fraction, diabetes mellitus, guideline‐directed medical therapy score, systolic and diastolic blood pressure, body mass index, log‐transformed baseline NT‐proBNP, New York Heart Association class, ischemic heart disease history, history of cancer in past 5 years, sleep apnea, and treatment arm. HR indicates hazard ratio; and Ref., reference.